Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 13/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186942 | 0.88 | LPL (0.39) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL29856116 | 0.88 | LPL (0.39) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL21816690 | 0.85 | LPL (0.45) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL27080292 | 0.80 | ALDH1A1 (0.51) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL15947140 | 0.79 | LPL (0.44) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL18239899 | 0.79 | IRAK4 (0.36) | IRAK4LPLLIPGCSF1RCA1 | |
| SCHEMBL2430729 | 0.78 | LIPG (0.38) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL35210916 | 0.76 | NR4A2 (0.52) | CSF1R | |
| SCHEMBL31452590 | 0.75 | LPL (0.38) | IRAK4LPLLIPGCSF1RPRMT5 | |
| SCHEMBL31651744 | 0.75 | ADORA2A (0.46) | IRAK4LPLLIPGCSF1RPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | IRAK4 952/4885LPL 4415/4885LIPG 3839/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | IRAK4 952/4885LPL 4415/4885LIPG 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.